A Randomized, Double-blind, Placebo-controlled Clinical Trial Evaluating the Safety and Efficacy of Oral Recombinant Salmon Calcitonin (rsCT) in the Prevention of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture.

Trial Profile

A Randomized, Double-blind, Placebo-controlled Clinical Trial Evaluating the Safety and Efficacy of Oral Recombinant Salmon Calcitonin (rsCT) in the Prevention of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2014

At a glance

  • Drugs Calcitonin (Primary)
  • Indications Bone resorption; Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Sponsors Tarsa Therapeutics
  • Most Recent Events

    • 16 Oct 2012 Results presented at the 34th Annual Meeting of the American Society for Bone and Mineral Research.
    • 16 Oct 2012 Results have been presented at the American Society for Bone and Mineral Research (ASBMR) 2012 Annual Meeting according to a Tarsa Therapeutics media release.
    • 16 Oct 2012 Primary endpoint 'Lumbar-spine-bone-mineral-density' has been met according to a Tarsa Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top